JERSEY CITY, N.J., Aug. 29, 2018 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ: SCYX), a biotechnology company delivering innovative
therapies for difficult-to-treat and often life-threatening
infections, today announced that the Company will participate in
the following upcoming investor conferences:
- Baird's 2018 Global Healthcare Conference at the
InterContinental New York Barclay Hotel on Wednesday, September 5, 2018 at 2:00 p.m. ET.
- The H.C. Wainwright 20th Annual Global Investment
Conference at the St. Regis New York on Thursday, September 6, 2018 at 12:30 p.m. ET.
- The Oppenheimer Fall Summit at the Langham, New York, Fifth Avenue on Wednesday, September 26, 2018.
A live webcast of the Baird and HC Wainwright presentations will
be available on the Investors section of the Company's website:
www.scynexis.com. Replay of the presentations will be available
approximately two hours after each event and will be available for
two weeks following each presentation.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ:SCYX) is a
biotechnology company committed to positively impacting the lives
of patients suffering from difficult-to-treat and often
life-threatening infections by developing innovative therapies. The
SCYNEXIS team has extensive experience in the life sciences
industry, discovering and developing more than 30 innovative
medicines over a broad range of therapeutic areas. SCYNEXIS's lead
product candidate, ibrexafungerp (formerly SCY-078), is a novel
oral/IV antifungal agent in Phase 2 clinical and pre-clinical
development for the treatment of multiple serious and
life-threatening invasive fungal infections caused by
Candida and Aspergillus species. For more
information, visit www.scynexis.com.
CONTACT:
Investor Relations
Natalie
Wildenradt
Argot Partners
Tel: 212-600-1902
natalie@argotpartners.com
Media Relations
George E.
MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-inc-to-participate-in-upcoming-investor-conferences-300701931.html
SOURCE SCYNEXIS, Inc.